The College of American Pathologists (CAP), the American Society for Clinical Pathology (ASCP), and the American Society of Clinical Oncology (ASCO) collaborated to develop a clinical practice guideline that helps establish standard HER2 testing, improve the accuracy of the test interpretation, guide HER2-targeted therapies, and provide accurate, personalized care for patients with gastric cancer.

**HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline from the CAP-ASCP-ASCO**

- **11 Evidence-based Recommendations**
  - 969 articles reviewed
  - 116 studies included in the evidence synthesis

- **43,280**
  - 2016 gastroesophageal adenocarcinoma cases diagnosed in US

- **22%**
  - Patients with gastroesophageal cancers that are HER2+

- **HER2 Directed treatment**
  - Shown to improve the life span of patients with advanced gastric cancer